PAVmed is a medical device company employing a business model to bring innovative products from concept to commercialization with speed and capital efficiency, while enhancing and accelerating value creation.
PAVmed is building a deep pipeline of products encompassing a broad spectrum of clinical areas possessing attractive regulatory pathways and market opportunities currently exceeding $4 billion. The company currently has five lead products to provide multiple near-term value creation opportunities
The Company is led by a team of accomplished medical device entrepreneurs. The leadership team has previously successfully implemented its unique business model of creating value with modest capital investment in four single-product companies, each of which rapidly advanced towards commercialization. Two of these four products have been cleared and commercialized, while two products are currently undergoing FDA review. PAVmed leverages this unique business model.
By establishing a long-term multi-product company with access to public capital, the company plans to build an expanding pipeline of innovative products across a range of specialties and clinical conditions.
Recent Press Releases
3/16/18 4:05 pm EDTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that its previously disclosed offer to exchange Series W Warrants (Nasdaq: PAVMW, the “W Warrant”) for Series Z Warrants (the “Offer”) has been extended, in accordance with applicable rules and regulations governing tender offers, until 5:00 P.M., Eastern Time, on April 2, 2018, unless further extended or terminated.more...
3/14/18 10:33 am EDTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the Company’s innovative business model and review PAVmed’s lead products.more...
2/21/18 7:30 am ESTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced the filing of a warrant exchange offer (the “Warrant Offer”) with the U.S. Securities and Exchange Commission (the “SEC”) providing holders of the Company’s outstanding Series W Warrants (Nasdaq: PAVMW, the “W Warrant”) the right to exchange every two W Warrants for one Series Z Warrant (the “Z Warrantmore...